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Available online 10 May 2016Objective: The aim of this studywas to investigate the relationship between the breast arterial calciﬁcation (BAC)
and the plasma atherogenic index (PAI), atherogenic coefﬁcient (AC), Castelli risk index-I (CRI-I) and Castelli risk
index-II (CRI-II).
Methods: This retrospective study included 60 premenopausal women aged over 40 years with BAC onmammo-
grams and control group of 60 women without BAC. Serum glucose, triglyceride (TG), low-density
lipoproteincholesterol (LDLc), high-density lipoprotein-cholesterol (HDLc), and total cholesterol (TC), levels
were measured. Lipid indices were calculated using the appropriate formula.
Results: LDLc, non-HDLc levels were signiﬁcantly higher, HDLc levels were siginiﬁcantly lower in patient group
compared to the control group (p=0.007, p=0.027, andp=0.014, respectively). Patient grouphad signiﬁcant-
ly higher PAI, AC, CRI-I and CRI-II levels than the control group (p= 0.003, p= 0.002, p = 0.002 and p= 0.003,
respectively). A signiﬁcant positive correlation was found between BAC and PAI, AC, CRI-I and CRI-II (r = 0.267
and p= 0.003, r = 0.282 and p= 0.002, r = 0.282 and p= 0.002, r = 0.271 and p= 0.003, respectively). LDLc
and non-HDLc were positively correlated whereas HDLc was negatively correlated with the BAC (r = 0.188 and
p = 0.039, r = 0.202 and p = 0.027, r =−0.223 and p = 0.014, respectively).
Conclusion: BAC is a valuable tool for the prediction of deranged lipid proﬁle. Dyslipidemia, PAI, AC, CRI-I and
CRI-II are risk factors for the development of atherosclerosis. Our results indicate that BAC is potentially useful
tool for the detection of dyslipidemia and early atherosclerosis in premenopausal women.
© 2016 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Breast arterial calciﬁcation (BAC) on mammography is uncommon
in women less than 50 years old. The prevalence of BAC ranges from 9
to 17% and increases with age [1]. Several studies have found correla-
tions between BAC and hypertension, diabetes mellitus, cardiovascular
disease and cardiovascularmortality [2–4]. Similarly, BAChas predictive
value for cerebral, carotid and peripheral artery disease [5]. Current
guidelines recommend annual mammography screening for all healthy
women beginning at the age 40 for early detection of breast cancer.
BAC detected during routine mammography may provide potential in-
sights into metabolic disorders responsible for atherosclerosis. Many
epidemiological studies have shown that high levels of low-densityAksalur cad. Oyak sitesi sok. 38.
is an open access article under the Clipoprotein cholesterol LDLc, TG and low HDLc play an important role
in thepathogenesis of atherosclerosis [6]. AlthoughhighTG levels corre-
latewith the presence of small, dense LDLc particles and associatedwith
increased risk of coronary artery disease, the risks appear to have
neglected in NCEP ATP III target recommendations [6–8].
There are new cardiovascular risk predictors obtained by different
combinations of lipid proﬁle parameters. These are; atherogenic index
of plasma (PAI); based on two important parameters TG and HDLc,
both of which are independent risk factors for coronary artery disease
(CAD) [9]. Castelli risk index-I (CRI-I); calculated as (TC / HDLc), Castelli
risk index-II (CRI-II); as (LDLc/HDLc) is another fraction which involves
independent risk factors for CAD [10,11] and atherogenic coefﬁcient
(AC) calculated as {(TC − HDLc) / HDLc} is yet another ratio relying
on the signiﬁcance of HDLc in predicting the risk of CAD [12].
The purpose of this study was to investigate whether BAC has a
relation with PAI, AC, CRI-I and CRI-II in premenopausal women over
40 years of age.C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Example of breast arterial calciﬁcation.
Table 1
Patient's clinical, lipid proﬁle and ratios among study groups.
Parameters BAC + (N:60) BAC− (N:60) P
Age 45.1 ± 3.1 45.6 ± 3.6 0.3
BMİ (kg/m2) 27.4 ± 1.4 26.2 ± 1.8 0.5
Systolic tension (mm Hg) 127.1 ± 8.3 126.3 ± 9.3 0.7
Diastolic tension (mm Hg) 72.5 ± 9.8 70.1 ± 7.3 0.6
Lipid proﬁle (mg/dl)
TC 207.7 ± 22.9 201.8 ± 18.4 0.135
HDLc 46.5 ± 7.2 49.6 ± 5.8 0.014
LDLc 133.2 ± 23.2 122.8 ± 18.3 0.007
TG 150.8 ± 12.3 146.9 ± 12.2 0.093
Non HDLc (TC− HDLc) 161.1 ± 23.5 152.2 ± 18.8 0.027
Lipid ratios
Atherogenic index of plasma 0.51 ± 0.07 0.47 ± 0.06 0.003
Atherogenic coefﬁcient 3.55 ± 0.83 3.12 ± 0.60 0.002
Castelli's risk index-I 4.55 ± 0.83 4.12 ± 0.60 0.002
Castelli's risk index-II 2.89 ± 0.75 2.52 ± 0.53 0.003
P value ≤ 0.05 is considered statistically signiﬁcant, BAC: breast arterial calciﬁcation, BMI:
Body mass index, TC: total cholesterol, HDLc: high density lipoprotein cholesterol, LDLc:
low density lipoprotein cholesterol, TG: triglyceride.
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2597 consecutive premenopausal women over 40 years of age that
were sent for screening anddiagnosticmammography between January
and November 2015 were recruited for this retrospective study. The
study protocol was approved by theMedipol University Ethics Commit-
tee. A Mammomat 3000 Nova equipment (Siemens AG, Germany) was
utilized for acquisition of craniocaudal andmediolateral oblique images.
If calciﬁcationswere present on the right, left, or both projections of the
breast, the mammogramwas categorized as BAC (+). BAC was deﬁned
as two linear calciﬁcation depositions in a conical periphery when the
arterial wall is imaged longitudinally or as calciﬁc rings when the artery
is cut transversely [2]. The women were divided into two groups: those
with BAC and those without BAC. 125 women with BAC were included
in the study. The women in postmenopausal state or having obesity,
past history of hypertension, liver disease, renal disease, diabetes
mellitus, thyroid dysfunction, coronary artery disease, valvular heart
disease, cerebrovascular disease and malignancy were excluded from
the study. A total of 60 women met all study criteria were entered in
the study and 60 subjects without BAC accepted as the control group.
Allwomenwere contacted by telephone andunderwent physical exam-
ination. All subject underwent 12-lead ECG (Comen CM100B, China) in
the supine position. Echocardiographic examinations were performed
using Vivid 3 pro equipment (GE Vingmed Ultrasound AS, Horten,
Norway) according to the guidelines of the American Society of Echo-
cardiography [13]. All blood samples were taken from antecubital vein
in the morning, after overnight fasting. All samples were evaluated on
the same day. Serum TC, TG, HDLc levels were assayed on Cobas c311
clinical chemistry analyzer (Roche Diagnostics, Germany). Serum LDLc
calculated using Freidwald formula [14]. Non-HDLc is calculated as
total cholesterol minus HDLc. The atherogenic ratios were calculated
as follows: PAI = log TG / HDLc, CRI-I = TC / HDLc, CRI-II = LDLc /
HDLc, AC = (TC− HDLc) / HDLc.
3. Statistical analysis
Continuous variables are expressed as mean ± SD. Categorical vari-
ables are expressed as percentages. To compare parametric continuous
variables, Student's t-test was used; and to compare categorical vari-
ables, the Chi square-test was used. Pearson's correlation analysis was
used for relation between BAC lipid parameters. All variables are show-
ing signiﬁcant values b 0.05. Two-tailed P values less than 0.05 were
considered signiﬁcant and the conﬁdence interval was 95%. All statisti-
cal studies were carried out using the SPSS program (version 22.0; SPSS
Inc., Chicago, Illinois, USA).
4. Results
2597 consecutive premenopausal women that were sent for screen-
ing and diagnostic mammography were evaluated and 60 women with
BAC who met entry criteria were enrolled in the study. (An example of
breast arterial calciﬁcation is shown in Fig. 1). 60 subjects without BAC
accepted as the control group. The demographic characteristics of both
groups including age, height, weight, body mass index (BMI), blood
pressure were similar. Both groups had BMI N 25 kg/m2 indicating over-
weight. Serum LDLc and non-HDLc levels of the patient group were sig-
niﬁcantly higher than the control group (p = 0.007 and p = 0.027,
respectively), whereas serum HDLc level of the patient group was
lower than the control group (p = 0.014) PAI, AC, CRI-I and CRI-II
were found to be increased signiﬁcantly in the patient group as
compared to their values in the control group (p = 0.003, p = 0.002,
p= 0.002 and p=0.003, respectively) (Table 1). Pearson bivariate cor-
relations analysis results showed that BAC was positively correlated
with non-HDLc and LDLc levels (r = 0.202, p = 0.027 and r = 0.188,
p = 0.039, respectively) and negatively correlated with HDLc levels
(r = 0.223, p = 0.014). There was a signiﬁcant positive correlationbetween BAC and PAI, AC, CRI-I and CRI-II (r = 0.267 and p = 0.003,
r = 0.282, and p = 0.002, r = 0.282 and p = 0.002, r = 0.273 and
p = 0.003, respectively) (Table 2).
Table 2
Pearson's correlations between BAC and lipid proﬁle and ratios.
Parameters r p
Plasma atherogenic index 0.267 0.003
Atherogenic coefﬁcient 0.282 0.002
Castelli's risk index-I 0.282 0.002
Castelli's risk index-II 0.271 0.003
Non-HDLc 0.202 0.027
TC 0.137 0.135
HDLc −0.223 0.014
LDLc 0.188 0.039
P value ≤ 0.05 is considered statistically signiﬁcant, TC: total cholesterol, HDLc: high den-
sity lipoprotein cholesterol, LDLc: low density lipoprotein cholesterol, TG: triglyceride.
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Atherosclerosis is a systemic disease. Arterial calciﬁcations are
predictor of cardiovascular disease. New diagnostic techniques now
allow noninvasive visualization of calciﬁcations within the walls of the
coronary and peripheral arteries. Several studies have evaluated the
relationship between BAC and CAD. The majority of these studies
demonstrated a positive association between BAC and CAD [5]. BAC
has been associated with age, diabetes, hypertension, osteoporosis,
hypertriglyceridemia, chronic kidney disease, albuminuria, hyperho-
mocysteinemia, BMI and high levels of hs-CRP [15–18]. We excluded
from the study all women who had all the risk factors listed above
except hyperlipidemia.
Pathologically calciﬁcation occurs at 2 anatomic sites within the vas-
cularwall; the intima and themedia. These different locations represent
2 pathophysiologically different processes [19–21]. Intimal calciﬁcation
is an active, regulated process that is similar to bone formation and
involves expression of growth factors, matrix proteins, and other
bone relate proteins [22], and has been associated with inﬂammatory
cells, lipid deposits, and vascular smooth muscle cells. Medial arterial
(Mönckeberg type) calciﬁcation occurs in the absence of macrophages
or lipid deposits [23]. Studies have conﬁrmed that medial calciﬁcation
is an independent predictor of CAD events. Although, intimal calciﬁca-
tion is more frequently associated with coronary artery disease, the im-
aging techniques used cannot distinguish between intimal and medial
calciﬁcation.
In this study,we investigated the relationship between BAC and lipid
indices. To the best of our knowledge, no study has described the asso-
ciation between BAC and PAI, AC, CRI-I and CRI-II in premenopausal
women.
A gradual change in ovarian function and estrogen production be-
gins at age 40. As estrogen levels decline lipid proﬁles change adversely,
increasing women's risk for atherosclerosis. Estrogen increases the
blood levels of HDLc, which have cardiovascular protective effects,
while lowering the levels of LDLc and TC, which increase the risk of car-
diovascular disease [24–26]. Dyslipidemia is one of the most important
risk factors for atherosclerosis. High levels of LDLc, TG and low levels of
HDLc are associated with increased CAD risk [27,28]. In addition to the
traditional lipid parameters, lipid indices have been used to assess the
risk of atherosclerosis. It has been suggested that the different combina-
tions of these lipid proﬁle parameters can be used to identify such high
risk individuals. PAI, CRI and AC are the three ratios predicting the risk
atherosclerosis and CAD. These are the calculated fractions which can
be used in the clinical setting for assessing the risk of cardiovascular dis-
ease beyond the routinely done lipid proﬁle. Atherogenic lipoprotein
phenotype is characterized by high TG, low HDLc and rise in small
dense LDLc [29]. It has been suggested that PAI values of −0.3 to 0.1
are associated with low, 0.1 to 0.24 with medium and above 0.24 with
high cardiovascular risk [30]. In our study PAI of the study group was
0.51 ± 0.07. High PAI values may be connected with the increased
risk of cardiovascular disease.In PROCAM study, it was observed that subjects with LDLc/HDLc N 5
had six times higher rate of coronary events [31]. Studies have shown
non-HDLc being similar to Apo-B in assessing atherogenic cholesterol
and lipoprotein burden [32]. The aforementioned observations suggest
that lipid ratios like PAI, CRI and AC could be used for identifying indi-
viduals at higher risk of atherosclerosis and cardiovascular disease,
when the absolute values of individual lipoproteins seem normal and
in individuals with elevated TG concentrations.
Our study showed that premenopausal women N40 years old with
BAC had altered lipid proﬁle and PAI, AC, CRI-I and CRI-II values. A num-
ber of clinical trials have shown that alterations in these parameters are
important risk factor for CAD and BAC is associated with CAD.
6. Study limitations
There are several limitations in this study. The osteoporotic status
and vitamin D levels of the women were not evaluated. Inﬂammatory
markers such as CRP, RDW were not assessed in the study population.
Visual scoring of conventional mammography was applied in BAC
assessment, the calciﬁcation mass scoring which have been used at
the digital mammography was not performed.
7. Conclusion
BAC detected during routinemammography is an important ﬁnding,
since they may indicate an increased risk for CAD. Evaluation of lipid
proﬁle and lipid indices (PAI, AC, CRI-I and CRI-II) of these patients
contributes to risk assessment and identiﬁes an important proportion
of dyslipidemia. Women with BAC require careful evaluation for the
presence of coronary artery disease. Improvements in cardiovascular
risk factors, including BMI, lipid pattern would therefore be of great
importance.
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